Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Financing Cardiovascular Business Strategies

Corteria Rides Wave Of Renewed Interest In Heart Failure

Raises €65m In Series A

  • Interviews

Executive Summary

A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.

You may also be interested in...



Novo Nordisk STEPs Into Heart Failure

The company’s metabolic juggernaut looks like a winner in obesity plus HFpEF, but making comparisons with approved products is tricky – and meeting demand is trickier still.

Farxiga Matches Jardiance And Cements SGLT2 Benefits In Heart Failure

Treatment with Farxiga led to an 18% reduction in a composite endpoint comprising cardiovascular death or worsening heart failure, putting it in the same ballpark as Boehringer Ingelheim and Eli Lilly's Jardiance and its 21% reduction shown in the EMPEROR-Preserved trial last year.

Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda

CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model. 

Table

View full table

Topics

Related Companies

Tags:
Financing Cardiovascular Business Strategies
Latest Headlines

Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18

Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

ViiV In It For The Long Haul In HIV Market Battle With Gilead

See All
UsernamePublicRestriction

Register

SC149002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By